Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €62.00 EUR
Change Today +0.75 / 1.22%
Volume 51.3K
As of 11:35 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

adocia sas (ADOC) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/6/15 - €75.50
52 Week Low
05/19/14 - €9.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADOCIA SAS (ADOC)

Related News

No related news articles were found.

adocia sas (ADOC) Related Businessweek News

No Related Businessweek News Found

adocia sas (ADOC) Details

Adocia, a biotechnology company, develops medicines from therapeutic proteins. The company focuses on insulin therapy and the treatment of diabetic foot ulcer based on its BioChaperone technological platform. Its product pipeline includes BioChaperone PDGF-BB, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase II clinical trials, as well as in pre clinical stage for the treatment of diabetes; and Driveln, which is preclinical stage for the treatment of oncology. The company, through its collaboration partnerships with pharmaceutical companies, also develops formulations for monoclonal antibodies. Adocia Société Anonyme was founded in 2005 and is based in Lyon, France.

74.6 Employees
Last Reported Date: 03/10/15
Founded in 2005

adocia sas (ADOC) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €280.0K
Co-Founder, Vice-President, Director of Resea...
Total Annual Compensation: €191.4K
Compensation as of Fiscal Year 2013.

adocia sas (ADOC) Key Developments

Adocia Announces Financial Results for the First Quarter Ended Mar. 31, 2015

Adocia announced financial results for the first quarter ended Mar. 31, 2015. For the quarter, the company reported revenue of €5,883,000 against €84,000 for the same period of last year. Revenue for the first quarter of 2015 result primarily from the licensing agreement signed with Eli Lilly in December 2014, relating to the development of an ultra-rapid insulin BioChaperone® Lispro. Specifically, it includes €2.7 million in licensing revenue reflecting the up-front payment received upon signature of the agreement with Eli Lilly. Under IFRS rules, the total up-front amount of €40.8 million is recognized as revenue linearly over the duration of the program as anticipated at the time of the signature of the agreement, whereas under French Gaap, the total up-front payment was recognized as revenue in 2014. Additionally, as per the agreement, the company invoiced Eli Lilly €3.2 million for internal and external expenses related to the co-development of the project, accounted for as research and collaborative agreements revenue. The total cash burn rate for the first quarter was €3 million, of which €5.7 million relates to the operating cash flow. This reflects the intensification of clinical activities per the operational plan and as defined in the strategy. Financial debt at end of March 2015, as end of December 2014, totaled €2.4 million and is mainly comprised of reimbursable advances received from the French agency for Innovation BpiFrance Financement (formerly Oséo), related to osteoporosis and insulin projects.

Adocia Société Anonyme, 2014 Earnings Call, Mar 17, 2015

Adocia Société Anonyme, 2014 Earnings Call, Mar 17, 2015

Adocia Opens Subsidiary in the USA; Announces Executive Changes

Adocia announced the creation of a subsidiary in the USA, Adocia Incorporated. Opening a US subsidiary is a key step in Adocia’s strategy, the USA are currently the primary market for its products. Adocia has developed BioChaperone® pipeline products in order to improve the insulin based treatments for diabetes, monoclonal antibodies and growth factors for the diabetic foot ulcer healing. Last December 2014, Adocia announced an alliance with Eli Lilly to co-develop BioChaperone Lispro, which is one of its products for the treatment of diabetes. The company announced the accompanying appointments of Simon Bruce, MD and Stephen Daly. Two employees are already appointed, Simon Bruce, M.D., Chief Medical Officer and Stephen Daly, US Commercial Lead who is in charge of the business development in the USA and also of the US investors relations. Dr. Bruce, who originally trained in endocrine clinical research at the National Institutes of Health in Bethesda, MD, has over 15 years of experience drug development and registrational drug trials. In his last job at Halozyme Pharmaceuticals, Dr. Bruce held a position as an Executive Medical Director working on the ultra-rapid insulin program. Stephen Daly has 24 years of experience in commercialization and business development for pharmaceutical and biotech products across multiple therapeutic categories. Most recently, he served as the Vice President of Commercial at Halozyme Therapeutics for their ultra-rapid insulin program.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADOC:FP €62.00 EUR +0.75

ADOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADOC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 84.9x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADOCIA SAS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at